文献速递呼吸道感染呼吸危重症与机械通气

血管生成素-1/-2在肺炎中的预后与致病作用

Prognostic and Pathogenic Role of Angiopoietin-1 and -2 in Pneumonia.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

该研究在148例和395例两个独立肺炎队列中检测血清血管生成素水平,并结合人尸检肺组织、内皮细胞、离体灌注通气小鼠肺及肺炎链球菌肺炎小鼠模型,探讨血管生成素-1/-2对肺血管屏障功能和炎症的影响。结果显示肺炎患者血清血管生成素-1降低、血管生成素-2升高,血管生成素-2升高与28天死亡相关,联合CURB-65可提高预后判断准确性,血管生成素-1治疗可减轻小鼠肺炎炎症与通透性。

要点

  • 肺炎患者血清血管生成素-1降低、血管生成素-2升高,血管生成素-2升高与28天内死亡相关。
  • 血管生成素-2联合CURB-65可提高28天生存、ICU治疗和住院时长的预测准确性。
  • 血管生成素-1可减轻肺炎链球菌肺炎小鼠的炎症与肺血管通透性,或为重症肺炎治疗靶点。

核心结论

  • 血管生成素-1/-2在肺炎所致炎症和通透性中起核心作用。
  • 血清血管生成素-2升高可预测肺炎患者死亡和住院时长。
  • 血管生成素-1可能成为重症肺炎的治疗靶点。

研究设计与样本

  • 在两个独立肺炎患者队列(n=148、n=395)中定量检测血清血管生成素水平。
  • 研究人尸检肺组织、肺炎链球菌溶血素或血管生成素-2刺激的内皮细胞。
  • 使用离体灌注通气小鼠肺及肺炎链球菌肺炎小鼠模型。

主要发现

  • 与健康受试者相比,肺炎患者血清血管生成素-1降低、血管生成素-2升高。
  • 社区获得性肺炎患者中,诊断后28天内死亡者血清血管生成素-2水平高于存活者。
  • ROC分析显示血管生成素-2联合CURB-65可提高对28天生存、ICU治疗和住院时长的预测准确性。
  • 体外实验中肺炎链球菌溶血素促进内皮释放血管生成素-2,血管生成素-2增加内皮通透性,血管生成素-1减轻溶血素所致内皮通透性升高。
  • 血管生成素-2敲低小鼠的灌注通气肺在溶血素刺激下通透性降低;肺炎链球菌感染小鼠肺内血管生成素-2升高、血管生成素-1 mRNA降低。

关键数值与推荐

  • 血清血管生成素水平在两个独立肺炎队列中定量,样本量分别为n=148和n=395。
  • 血管生成素-2联合CURB-65用于评估28天生存、ICU治疗和住院时长的预测准确性。
  • 小鼠模型中血管生成素-1治疗可减轻肺炎相关炎症和通透性。

临床怎么用

  • 血清血管生成素-2或可作为肺炎预后评估的补充指标,与CURB-65联合使用。
  • 血管生成素-1/-2通路可能成为重症肺炎的潜在治疗方向,尚需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: During pneumonia, pathogen-host interaction evokes inflammation and lung barrier dysfunction. Tie2 activation by angiopoietin-1 reduces, whereas Tie2 blockade by angiopoietin-2 increases, inflammation and permeability during sepsis. The role of angiopoietin-1/-2 in pneumonia remains unidentified. OBJECTIVES: To investigate the prognostic and pathogenic impact of angiopoietins in regulating pulmonary vascular barrier function and inflammation in bacterial pneumonia. METHODS: Serum angiopoietin levels were quantified in pneumonia patients of two independent cohorts (n = 148, n = 395). Human postmortem lung tissue, pneumolysin- or angiopoietin-2-stimulated endothelial cells, isolated perfused and ventilated mouse lungs, and mice with pneumococcal pneumonia were investigated. MEASUREMENTS AND MAIN RESULTS: In patients with pneumonia, decreased serum angiopoietin-1 and increased angiopoietin-2 levels were observed as compared with healthy subjects. Higher angiopoietin-2 serum levels were found in patients with community-acquired pneumonia who died within 28 days of diagnosis compared with survivors. Receiver operating characteristic analysis revealed improved prognostic accuracy of CURB-65 for 28-day survival, intensive care treatment, and length of hospital stay if combined with angiopoietin-2 serum levels. In vitro, pneumolysin enhanced endothelial angiopoietin-2 release, angiopoietin-2 increased endothelial permeability, and angiopoietin-1 reduced pneumolysin-evoked endothelial permeability. Ventilated and perfused lungs of mice with angiopoietin-2 knockdown showed reduced permeability on pneumolysin stimulation. Increased pulmonary angiopoietin-2 and reduced angiopoietin-1 mRNA expression were observed in Streptococcus pneumoniae-infected mice. Finally, angiopoietin-1 therapy reduced inflammation and permeability in murine pneumonia. CONCLUSIONS: These data suggest a central role of angiopoietin-1/-2 in pneumonia-evoked inflammation and permeability. Increased angiopoietin-2 serum levels predicted mortality and length of hospital stay, and angiopoietin-1 may provide a therapeutic target for severe pneumonia.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Gutbier B, Neuhauß AK, Reppe K, et al. Prognostic and Pathogenic Role of Angiopoietin-1 and -2 in Pneumonia. Am J Respir Crit Care Med. 2018. PMID: 29447449. doi:10.1164/rccm.201708-1733OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。